Replies to post #105051 on Biotech Values

[randychub]

"The cash-flow leverage from mL sales provides MNTA the opportunity to be creative in their approach to partnering M118"

I would speculate that this means they can back load any M118 deal. This would not profile much of short term lift in our PPS.

Anyone here think we need Capaxone approval before we start inking deals for other biologics?

R